News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Exelixis, Inc. (EXEL) Announces Presentation of Updated Phase 1b Data for Cobimetinib (GDC-0973/XL518) in Combination with Vemurafenib at ECC 2013


9/30/2013 6:41:08 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

Exelixis, Inc. (NASDAQ:EXEL) today announced updated results from BRIM7, an ongoing phase 1b clinical trial conducted by Roche and Genentech, Exelixis' collaborator and a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), of the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor cobimetinib (GDC-0973/XL518) in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAFV600 mutation. Grant McArthur, M.D., Head of the Medical Oncology Skin and Melanoma Clinical Service at the Peter MacCallum Cancer Centre in Australia, and an investigator on the trial, presented the data today at the European Cancer Congress (ECC) 2013 (Abstract #3703) which is taking place in Amsterdam, The Netherlands.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES